Is HRT Safe for the Heart? 2026 Safety & Risks Guide

What the Evidence Actually Says About HRT and Heart Health

The short answer is that HRT is cardiovascularly safe, and possibly beneficial, for most healthy women who start it early. The longer answer requires unpacking two decades of evolving data, beginning with a trial that scared an entire generation of patients and prescribers.

The Women's Health Initiative (WHI), published in 2002, reported that combined conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) increased coronary heart disease (CHD) events. That headline effectively halved HRT prescriptions across the United States within three years. What received far less attention was the subsequent subgroup reanalysis showing that the elevated risk was concentrated almost entirely in women who were 10 or more years past menopause when they enrolled.

The WHI Reanalysis Changed Everything

Rossouw et al. Published a 2007 age-stratified analysis in JAMA showing that women aged 50-59 on CEE alone had a hazard ratio of 0.68 for CHD (a 32% relative risk reduction) versus placebo (1). Women aged 70-79 starting the same therapy had a hazard ratio of 1.28. The age-interaction P-value was 0.05, indicating the direction of effect genuinely reversed with age at initiation.

This is the foundation of what endocrinologists now call the "timing hypothesis" or "window of opportunity."

What "Timing Hypothesis" Means Clinically

The timing hypothesis holds that estrogen is vasculoprotective on healthy, estrogen-receptive endothelium but may accelerate atherosclerotic plaque rupture when applied to already-diseased arterial walls. A 2004 paper by Clarkson in the American Journal of Cardiology using non-human primate models showed that estrogen reduced coronary artery plaque by 70% when given immediately after oophorectomy, and had no benefit when given 2 years later (2). The arterial biology essentially resets the risk calculation depending on vascular age at the time of initiation.

The 2022 Menopause Society (NAMS) position statement formalizes this: "For women who are younger than 60 years of age or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" (3).

How Route of Delivery Changes Cardiovascular Risk

Route matters as much as timing. Not all estrogen delivery systems carry the same clot and stroke profile.

Oral Estrogen and VTE Risk

Oral estrogen undergoes first-pass hepatic metabolism, which raises coagulation factor synthesis (particularly factor VII and fibrinogen) and lowers protein S. The E3N cohort study (N=80,308 French women, follow-up median 8.4 years) found that oral estrogen users had a venous thromboembolism (VTE) risk roughly twice that of never-users, while transdermal users showed no statistically significant increase (relative risk 1.1, 95% CI 0.8-1.8) (4).

A 2019 BMJ analysis by Vinogradova et al. (N=1,028,553 women) confirmed this finding, reporting an odds ratio for VTE of 1.58 for oral estradiol versus 0.93 for transdermal estradiol (5).

Transdermal Estrogen and Stroke Risk

Ischemic stroke risk with oral estrogen at standard doses (0.625 mg CEE or 2 mg oral estradiol) runs approximately 32 additional events per 10,000 woman-years. Transdermal estradiol at doses of 50 mcg or below does not appear to carry that same elevation.

The ESTHER study (Etude Epidémiologique de Femmes de la MGEN) found no increased stroke risk for transdermal estrogen (OR 0.83, 95% CI 0.56-1.24) while oral estrogen conferred an OR of 1.89 (6).

Why This Matters for Prescribing Decisions

Women with additional VTE risk factors (factor V Leiden mutation, obesity with BMI <35 but borderline, or prior superficial thrombosis) should be offered transdermal, not oral, estrogen as the default. The North American Menopause Society 2022 statement and the British Menopause Society 2023 guidelines both support transdermal as the preferred route in higher-risk patients.

The Progestogen Problem: Progesterone vs. Synthetic Progestins

Women with an intact uterus require a progestogen to protect the endometrium from unopposed estrogen. The cardiovascular profile of that progestogen is not neutral.

MPA vs. Micronized Progesterone

Medroxyprogesterone acetate (MPA, sold as Provera) was the progestin used in the WHI. It has partial glucocorticoid and androgenic activity that may partly explain the cardiovascular signal seen in the combined-arm trial. Micronized progesterone (Prometrium, 100-200 mg oral or vaginal) is biochemically identical to endogenous progesterone and lacks those receptor cross-effects.

The E3N cohort (referenced above) found that women using estrogen combined with micronized progesterone had no significant increase in breast cancer risk compared with never-users, and separate cardiovascular data from the same cohort showed a VTE hazard ratio of 0.9 (95% CI 0.6-1.5) for transdermal estrogen plus micronized progesterone, compared with 3.5 for oral estrogen plus MPA (4).

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727, 4-year follow-up) found no difference between low-dose oral CEE and transdermal estradiol versus placebo in coronary artery calcium progression, but this trial began in recently menopausal women and used micronized progesterone as the progestogen across the active arms (7).

Dydrogesterone as an Alternative

Dydrogesterone (Duphaston, not yet widely available in the US but used extensively in Europe) shows a cardiovascular profile broadly similar to micronized progesterone in observational data. A 2020 retrospective analysis published in Climacteric found dydrogesterone combined with estradiol carried a lower breast cancer relative risk than MPA-containing regimens, and cardiovascular event rates trended similarly (8).

The DOPS Trial: The Strongest RCT Evidence for Early HRT Cardioprotection

The Danish Osteoporosis Prevention Study (DOPS) is the randomized controlled trial that most directly tests the timing hypothesis.

Trial Design and Results

DOPS randomized 1,006 recently menopausal women (mean age 50 years, within 6 months to 24 months of last period) to triphasic oral estradiol-norethisterone acetate or no treatment, with a 10-year intervention period and 6 additional years of follow-up. After 16 years total, the HRT group showed a 52% reduction in the composite endpoint of mortality, myocardial infarction, and heart failure (HR 0.48, 95% CI 0.26-0.87, P=0.015) (9).

This is among the largest and longest RCT datasets supporting cardiovascular benefit from early-initiated HRT. The trial used an oral norethisterone formulation, not MPA, which may account for the difference from WHI outcomes.

Limitations to Keep in Mind

DOPS was not blinded after year 10 (participants could choose to continue or stop), and the synthetic progestogen used differs from current best-practice recommendations. Still, the directional finding holds: early initiation in healthy women does not increase cardiovascular events and may reduce them.

Women Who Should Avoid HRT or Use Extreme Caution

Not every woman is a candidate. The cardiovascular safety data applies primarily to healthy women who initiate HRT near menopause. Several subgroups face genuinely elevated risk.

Established Cardiovascular Disease

Women with a prior MI, unstable angina, or coronary artery disease have calcified and vulnerable plaque. Applying estrogen to those vessels may destabilize plaques rather than protect them, consistent with the WHI older-cohort findings. The Heart and Estrogen/Progestin Replacement Study (HERS, N=2,763) found no reduction in recurrent CHD events in women with pre-existing CHD starting combined HRT, with a trend toward early harm in year one (10). HRT is not indicated for secondary cardiovascular prevention.

Prior VTE or Known Thrombophilia

Oral estrogen significantly raises VTE risk. Women with a personal history of DVT, PE, or a confirmed thrombophilia (factor V Leiden homozygous, antiphospholipid syndrome) should not use oral estrogen. Transdermal estrogen may be considered with specialist input, but risk-benefit weighing must be individualized.

Uncontrolled Hypertension

Systolic blood pressure above 160 mmHg represents a contraindication to standard-dose estrogen therapy in most guidelines. Blood pressure should be controlled to below 140/90 mmHg before initiating HRT.

More Than 10 Years Post-Menopause Without Prior HRT Use

Starting de novo HRT more than 10 years after menopause in a woman who has never used it falls outside the timing window. If vasomotor symptoms are still present and quality of life is severely affected, a specialist risk-benefit discussion is warranted, but the cardiovascular calculus is genuinely less favorable.

Absolute Versus Relative Risk: Putting the Numbers in Context

Relative risk figures dominate medical headlines, but absolute risk numbers are what matter to a patient sitting in a clinic.

The table below uses WHI and E3N data to illustrate absolute risks per 10,000 woman-years for women aged 50-59 starting HRT within 10 years of menopause, compared with non-users.

| Outcome | Non-user baseline | Oral CEE+MPA | Transdermal E2 + micronized P4 | |---|---|---|---| | Coronary heart disease | ~39 events | ~36 events (WHI 50-59 subgroup) | ~30-35 events (estimated) | | VTE | ~17 events | ~34 events | ~18-19 events | | Ischemic stroke | ~21 events | ~29 events | ~21 events | | Hip fracture | ~15 events | ~10 events | ~10 events |

These figures are approximations drawn from WHI subgroup data (1) and E3N cohort data (4). Individual patient risk depends on baseline blood pressure, BMI, smoking status, and family history.

For most healthy women aged 50-59 who start transdermal estradiol with micronized progesterone within 10 years of menopause, the added absolute cardiovascular risk is close to zero, and hip fracture benefit is real.

Current Guideline Positions in 2026

Guidelines have converged considerably since the initial WHI panic.

NAMS 2022

The North American Menopause Society 2022 position statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture... For women who are younger than 60 years of age or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable" (3).

The statement explicitly notes that cardiovascular disease and coronary heart disease are not listed as contraindications for appropriately selected, early-initiating women.

British Menopause Society 2023

The BMS 2023 guidance reaffirms that transdermal estrogen with micronized progesterone or dydrogesterone is the preferred regimen for women at any elevated thrombotic risk, and endorses the timing hypothesis as the basis for initiating decisions. The guidance also notes that HRT does not need to be stopped at age 60 if it was started appropriately and the woman remains symptom-free with ongoing benefit.

ESC / AHA Position

The European Society of Cardiology 2021 guidelines on cardiovascular disease in women state that HRT should not be used for primary or secondary prevention of cardiovascular disease, but acknowledge that early initiation in symptomatic women does not increase risk and that transdermal delivery is preferred when VTE risk is a concern (11).

The American Heart Association echoes this: HRT is not a cardiovascular prevention strategy, but appropriately timed symptomatic treatment does not carry meaningful added cardiovascular risk for healthy, younger postmenopausal women.

Practical Decision Points for Clinicians and Patients

The clinical question is never "is HRT safe in the abstract?" but rather "is HRT safe for this specific woman, starting at this age, on this regimen?"

The Five Questions That Govern Risk Stratification

1. How long since her last menstrual period? Under 10 years is the target window.
2. Does she have established cardiovascular disease? If yes, HRT is not appropriate for routine use.
3. Does she have a personal or family history of VTE or a known thrombophilia? If yes, transdermal estrogen only, with specialist input.
4. Is her blood pressure controlled? Treat to below 140/90 mmHg before initiating.
5. Does she still have a uterus? If yes, she needs a progestogen. Choose micronized progesterone (Prometrium 100 mg nightly) or dydrogesterone over MPA wherever possible.

Monitoring After Starting HRT

Blood pressure should be rechecked at 3 months. Fasting lipids at 6 months are reasonable in women with borderline baseline LDL (above 130 mg/dL) since oral estrogen can raise triglycerides. Annual cardiovascular symptom review should be documented.

Women who develop new hypertension, migraine with aura, or unexplained leg swelling or pain after starting HRT should be evaluated promptly and HRT temporarily held pending assessment.

A Note on Testosterone and Cardiovascular Risk in Women

Low-dose testosterone is increasingly prescribed alongside HRT for libido and energy in perimenopausal and postmenopausal women. Current evidence does not show increased cardiovascular risk at physiological female-range doses (typically 0.5-2 mg transdermal testosterone daily). The NICE 2015 menopause guideline and the 2019 Global Consensus Position Statement on female testosterone both note the absence of cardiovascular harm signal at these doses, though long-term RCT data beyond 2 years remain limited (12).

Supraphysiological dosing (common in compounded testosterone preparations dosed at male-equivalent levels) raises LDL, lowers HDL, and raises hematocrit. Those effects carry real cardiovascular implications. Standard female dosing does not.